The CC was everything I expected and more with eps being higher then expected as I felt they would come in closer to in line due to the hiring costs associated with the expanded sales force. The balance sheet remains squeaky clean with gross margins maintaining a whopping 93%.
Going forward comments on the N/S front are very exciting and I like Cartt's idea of adding a small N/S sales force only to assist the company in the longer range plan to probe this market first as an exploratory expedition to determine the appropriate sales force required to achieve maximum penetration.
M/S continues to break records quarter over quarter and we may see some incremental I/S growth the 4th quarter as the marketing begins in earnest this quarter.
The flush you hear in the background are all the put option and short players going down the toliet as this stock is going to EXPLODE at the open on Friday!!!
Bailey now has the buyback lever firmly in hand and any profit taking intraday will provide some buying ops for Baily as he wants to get his 5mm shares before pps get away!
no specifics on "how" they'd do buyback, but they cited "unfortunately" they were not allowed to buy this entire year due to FDA application, and now they can. Further, they had discussed one-time stock dividend but it's too complicated especially going into yr end. Therefore, to increase shareholder value, besides running the business the only other way to deal w/ the excess cash is via stock buyback.